Stifel Financial Corp Cyma Bay Therapeutics, Inc. Transaction History

Stifel Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $81,675 - $184,410	-13,500 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$8.16 - $13.42 $12,240 - $20,130	1,500 Added 12.5%	13,500 $179,000
Q4 2018 Feb 13, 2019	SELL	$6.54 - $11.74 $22,890 - $41,090	-3,500 Reduced 22.58%	12,000 $96,000
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $79,950 - $107,850	-7,500 Reduced 32.61%	15,500 $207,000
Q1 2018 May 11, 2018	BUY	$9.0 - $15.16 $207,000 - $348,680	23,000 New	23,000 $297,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.